Elucida Oncology to Present at Two Upcoming Conferences
03 juin 2022 10h00 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that...
Elucida Oncology to Present Trials in Progress Poster for Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing FRα at 2022 American Society of Clinical Oncology Annual Meeting
01 juin 2022 13h30 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today the...
Elucida Oncology to Present at the Bank of America 2022 Healthcare Conference
06 mai 2022 11h00 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N. J. , May 06, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that...
Elucida Oncology’s Lead Clinical Candidate ELU001 to Be Featured in Two Abstracts at the American Association for Cancer Research Annual Meeting
04 avr. 2022 10h00 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today two...
Elucida Oncology to Present at Two Upcoming Scientific Conferences
03 mars 2022 13h30 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that Dr....
Elucida Oncology Provides Corporate Update and Outlines Key Upcoming Milestones
05 janv. 2022 08h02 HE
|
Elucida Oncology, Inc
Enrolling third dose level in Phase 1/2 dose escalation study of ELU001, our lead clinical program targeting solid tumors overexpressing folate receptor alpha (FRα) Interim Phase 1 data for ELU001 in...
Elucida Oncology to Present at Two Upcoming Investor Conferences
05 janv. 2022 08h00 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that Geno...
Elucida Oncology to Present Preclinical Data on ELU001 at the Antibody Engineering & Therapeutic Conference
15 déc. 2021 15h50 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that...
Elucida Oncology Appoints Ian Somaiya as Chief Financial Officer and Chief Business Officer
22 nov. 2021 07h30 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today the...
Elucida Oncology Announces First Patient Dosed in Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing Folate-Receptor Alpha (FRα)
17 sept. 2021 10h15 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that it has completed...